VivoSeq
Other

Hypercalcemia

8

Pipeline Programs↗

0

Active Trials↗

5

Companies Involved↗

Hypercalcemia is an early-stage landscape with 8 programs across 5 companies. The most active players are Sanofi, Amgen, Pfizer. 4 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

33/100

Pipeline Velocity

0/100

Mech. Concentration

57/100

Completion Rate

67/100

Attrition Rate

33/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Sanofi logo

Sanofi

1 program

Phase 2Amgen logo

Amgen

2 programs

Phase 2Pfizer logo

Pfizer

1 program

ApprovedP

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

ApprovedQ

Quince Therapeutics S.p.A.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

88%

Small molecule

7 of 8 classified programs — the dominant modality here.

13%ALL OTHERSMonoclonal antibody113%

Small molecule leads; the ring shows all 8 classified programs, each share of the total. Modality classified for 100% of 8 pipeline programs.

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Terminated1 · 33%

Clinical Trials

Trial Activity

Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium
Completed·Amgen logoAmgen·Phase 2·NCT00896454·33 enrolled
Zometa for the Management of Tumor-induced Hypercalcemia and Malignant Bone Pain in the Community
Completed·AAlberta Health services·N/A·NCT00126386·11 enrolled
Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients
Terminated·MMontefiore Medical Center·Phase 1/2·NCT00415584·4 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)